HBI Deals+Insights / News
Fresenius, Germany’s largest for-profit hospital group, has just released its 2024 annual results, and CEO Michael Sen’s “Future Fresenius” strategy is in full swing.
The company beat market expectations for FY24 earnings, with strong performance from its hospital drug unit, Kabi. The unit saw a 21% jump in EBIT year-on-year, hitting €340 million, driven by solid revenue growth and better productivity.





